Vemurafenib-induced progression of breast cancer: a case report and review of the literature
- 12 August 2015
- journal article
- case report
- Published by Springer Nature in Targeted Oncology
- Vol. 11 (2) , 235-238
Abstract
Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.Keywords
This publication has 15 references indexed in Scilit:
- BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemiaJournal of Clinical Investigation, 2014
- Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanomaInternal Medicine Journal, 2014
- Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant MalignanciesCancer Discovery, 2014
- BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 InhibitionJournal of Clinical Oncology, 2013
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With MelanomaThe Oncologist, 2013
- Progression of RAS-Mutant Leukemia during RAF Inhibitor TreatmentNew England Journal of Medicine, 2012
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionJournal of Clinical Oncology, 2012
- Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?Journal of Clinical Oncology, 2012
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010